-
平臺編號：bio-50007
-
國際編號：ATCC VR-2103
-
拉丁屬名： Gallid herpesvirus 2
-
規(guī)格：frozen
-
用途：ATCC原裝進口
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
Gallid herpesvirus 2
ATCC? Number:VR-2103?
Classification: Herpesviridae, Mardivirus
Agent: Gallid herpesvirus 2 deposited as Marek's disease virus type 1
Strain: MDV CVI-988 clone C
Original Source: Attenuation of CVI-988 strain derived from chickens in Europe
Depositors: Central Vet. Res. Inst.
Biosafety Level:2
Shipped: frozen
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Host Organism : chicken embryo fibroblasts chicken embryo fibroblasts; duck; chicken
Incubation : Temperature: 38.5°C Duration: 5-7 days
Effect : Yes, in vitro effects: Cytopathic effects (syncytium formation, cell rounding)
Comments : A vaccine strain, clone C, derived from Marek's disesase strain CVI-988, serotype-1 by serial passage in cell culture and plaque purification.
References : 3835: DeBoer GF. Live purified Marek's disease vaccine. US Patent 4,673,572 dated Jun 16 1987 33273: Rispens BH, et al. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis. 16: 108-125, 1972. PubMed: 4337307 33274: de Boer GF, et al. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains. Avian Dis. 30: 276-283, 1986. PubMed: 3015113 38282: Rispens BH, et al. Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus. Avian Dis. 16: 126-138, 1972. PubMed: 4337309
Classification: Herpesviridae, Mardivirus
Agent: Gallid herpesvirus 2 deposited as Marek's disease virus type 1
Strain: MDV CVI-988 clone C
Original Source: Attenuation of CVI-988 strain derived from chickens in Europe
Depositors: Central Vet. Res. Inst.
Biosafety Level:2
Shipped: frozen
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Host Organism : chicken embryo fibroblasts chicken embryo fibroblasts; duck; chicken
Incubation : Temperature: 38.5°C Duration: 5-7 days
Effect : Yes, in vitro effects: Cytopathic effects (syncytium formation, cell rounding)
Comments : A vaccine strain, clone C, derived from Marek's disesase strain CVI-988, serotype-1 by serial passage in cell culture and plaque purification.
References : 3835: DeBoer GF. Live purified Marek's disease vaccine. US Patent 4,673,572 dated Jun 16 1987 33273: Rispens BH, et al. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis. 16: 108-125, 1972. PubMed: 4337307 33274: de Boer GF, et al. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains. Avian Dis. 30: 276-283, 1986. PubMed: 3015113 38282: Rispens BH, et al. Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus. Avian Dis. 16: 126-138, 1972. PubMed: 4337309
